Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$68.20-5.38%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Tarsus Pharmaceuticals, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	204.8M
EPS	—	-0.076
FY 2026 · Annual
Revenue	Over $2B	727.34M
EPS	—	-2.107
FY 2027 · Annual
Revenue	—	922.69M
EPS	—	1.024

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Strengthen leadership with board expansion	The company expanded its board to strengthen leadership.	Intact	Board fails to add value or experiences turnover	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net losses and improve earnings	A primary condition in Tarsus Pharmaceuticals, Inc.'s published investment case. The stated target is Net loss narrows or turns positive by FY27.	Improving	Net loss persists or worsens beyond FY27	Diluted EPS: $-0.43 per share FY2026-Q2; GAAP. Published target: Net loss narrows or turns positive by FY27. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.43 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 452f2329-87de-4500-975c-9b47a452cc3e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve $670-700M XDEMVY sales in FY26	Tarsus aims to grow XDEMVY sales to $670-700M in 2026.	Intact	Revenue falls below $670M in FY26	Revenue: $173.912M FY2026-Q2; GAAP. Published target: >= $670M revenue. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026173,912,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 452f2329-87de-4500-975c-9b47a452cc3e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	2 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable	2 / 1
2026-07-30	Unavailable	Unavailable	2 / 1
2026-07-31	Unavailable	Unavailable	2 / 1
2026-08-01	Unavailable	Unavailable	2 / 1
2026-08-02	Unavailable	Unavailable	2 / 1
2026-08-03	Unavailable	Unavailable	2 / 1
2026-08-04	Unavailable	Unavailable	2 / 1
2026-08-05	Unavailable	Unavailable	2 / 1
2026-08-06	Unavailable	Unavailable	2 / 1
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-12	$2.19	$920,328,360	5 / 5
2026-08-13	$2.19	$920,328,360	5 / 5
2026-08-14	Unavailable	Unavailable	2 / 1
2026-08-15	Unavailable	Unavailable	2 / 1
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 2
2026-08-19	Unavailable	Unavailable	3 / 2
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	$1.42	$916,635,222	5 / 5
2026-09-27	Unavailable	$916,635,222	4 / 5
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	9	0	0
2026-07-01	9	0	0
2026-08-01	9	0	0
2026-09-01	10	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Strengthen leadership with board expansionQualitative condition
Reduce net losses and improve earningsDiluted EPS: $-0.43 per share
Achieve $670-700M XDEMVY sales in FY26Revenue: $173.912M

Next proof point

Nov 3, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-32.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Tarsus Pharmaceuticals, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a commercial-stage biotech growth story, with its current business led by XDEMVY and its longer-term prospects tied partly to pipeline development. The thesis is on watch: product growth is progressing, but recent financial performance is weak and the latest quarter missed expectations.

What's priced into Tarsus Pharmaceuticals, Inc.

The valuation evidence points to TARS as cheap versus peers, while the expectations gap is negative; model confidence is low. The overall priced-in tag is justified, and no fragility gates fired, but the evidence does not show that weak performance or earnings uncertainty is fully resolved.

What the fundamentals likely do

Near term, XDEMVY sales growth and higher 2026 guidance support the commercial story, while an elevated risk of another earnings miss weighs on the outlook. Over the multi-year view, acquisitions add late-stage clinical assets, but pipeline progress remains mixed and the NORTHSTAR trial's topline data is expected in 2029.

What Tarsus Pharmaceuticals, Inc. hinges on

The near-term test is whether TARS can deliver against its raised guidance without another miss or a reversal that damages management credibility. Over the multi-year view, the thesis also depends on continued XDEMVY adoption and pipeline execution; weaker employment data could pressure healthcare names, while strength among sector bellwethers could support sector momentum.

Bottom line

The 1-to-3-year view rests on a growing product base and pipeline expansion, balanced against weak recent results and meaningful execution risk. The available evidence supports a watch-state thesis, not a settled one. Not investment advice.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	204.8M
EPS	—	-0.076
FY 2026 · Annual
Revenue	Over $2B	727.34M
EPS	—	-2.107
FY 2027 · Annual
Revenue	—	922.69M
EPS	—	1.024

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

Unavailable → Unavailable · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 1
2026-07-25	Unavailable	Unavailable	1 / 1
2026-07-26	Unavailable	Unavailable	2 / 1
2026-07-27	Unavailable	Unavailable	1 / 1
2026-07-28	Unavailable	Unavailable	1 / 1
2026-07-29	Unavailable	Unavailable	2 / 1
2026-07-30	Unavailable	Unavailable	2 / 1
2026-07-31	Unavailable	Unavailable	2 / 1
2026-08-01	Unavailable	Unavailable	2 / 1
2026-08-02	Unavailable	Unavailable	2 / 1
2026-08-03	Unavailable	Unavailable	2 / 1
2026-08-04	Unavailable	Unavailable	2 / 1
2026-08-05	Unavailable	Unavailable	2 / 1
2026-08-06	Unavailable	Unavailable	2 / 1
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 4
2026-08-10	Unavailable	Unavailable	2 / 1
2026-08-12	$2.19	$920,328,360	5 / 5
2026-08-13	$2.19	$920,328,360	5 / 5
2026-08-14	Unavailable	Unavailable	2 / 1
2026-08-15	Unavailable	Unavailable	2 / 1
2026-08-16	Unavailable	Unavailable	3 / 3
2026-08-17	Unavailable	Unavailable	3 / 3
2026-08-18	Unavailable	Unavailable	3 / 2
2026-08-19	Unavailable	Unavailable	3 / 2
2026-08-20	Unavailable	Unavailable	4 / 3
2026-08-21	Unavailable	Unavailable	4 / 3
2026-08-22	Unavailable	Unavailable	4 / 3
2026-08-23	Unavailable	Unavailable	4 / 3
2026-08-24	Unavailable	Unavailable	4 / 3
2026-08-25	Unavailable	Unavailable	4 / 3
2026-08-26	Unavailable	Unavailable	4 / 3
2026-08-27	Unavailable	Unavailable	4 / 3
2026-08-28	Unavailable	Unavailable	4 / 3
2026-08-29	Unavailable	Unavailable	4 / 3
2026-08-30	Unavailable	Unavailable	4 / 3
2026-08-31	Unavailable	Unavailable	4 / 3
2026-09-01	Unavailable	Unavailable	4 / 3
2026-09-02	Unavailable	Unavailable	4 / 3
2026-09-03	Unavailable	Unavailable	4 / 3
2026-09-04	Unavailable	Unavailable	4 / 3
2026-09-05	Unavailable	Unavailable	4 / 3
2026-09-06	Unavailable	Unavailable	4 / 3
2026-09-07	Unavailable	Unavailable	4 / 3
2026-09-08	Unavailable	Unavailable	4 / 3
2026-09-09	Unavailable	Unavailable	4 / 4
2026-09-10	Unavailable	Unavailable	4 / 4
2026-09-11	Unavailable	Unavailable	4 / 4
2026-09-12	Unavailable	Unavailable	4 / 4
2026-09-13	Unavailable	Unavailable	4 / 4
2026-09-14	Unavailable	Unavailable	4 / 4
2026-09-15	Unavailable	Unavailable	4 / 4
2026-09-16	Unavailable	Unavailable	4 / 4
2026-09-17	Unavailable	Unavailable	4 / 4
2026-09-18	Unavailable	Unavailable	4 / 4
2026-09-19	Unavailable	Unavailable	4 / 4
2026-09-20	Unavailable	Unavailable	4 / 4
2026-09-21	Unavailable	Unavailable	4 / 4
2026-09-22	Unavailable	Unavailable	4 / 4
2026-09-23	Unavailable	Unavailable	4 / 4
2026-09-24	Unavailable	Unavailable	4 / 4
2026-09-25	Unavailable	Unavailable	4 / 4
2026-09-26	$1.42	$916,635,222	5 / 5
2026-09-27	Unavailable	$916,635,222	4 / 5
2026-09-28	Unavailable	Unavailable	3 / 3
2026-09-29	Unavailable	Unavailable	3 / 3
2026-09-30	Unavailable	Unavailable	3 / 3
2026-10-01	Unavailable	Unavailable	3 / 3
2026-10-02	Unavailable	Unavailable	3 / 3
2026-10-03	Unavailable	Unavailable	3 / 3
2026-10-04	Unavailable	Unavailable	3 / 3
2026-10-05	Unavailable	Unavailable	3 / 3
2026-10-06	Unavailable	Unavailable	3 / 3
2026-10-07	Unavailable	Unavailable	3 / 3
2026-10-08	Unavailable	Unavailable	3 / 3
2026-10-09	Unavailable	Unavailable	3 / 3
2026-10-10	Unavailable	Unavailable	3 / 3
2026-10-11	Unavailable	Unavailable	3 / 3
2026-10-12	Unavailable	Unavailable	3 / 3
2026-10-13	Unavailable	Unavailable	3 / 3
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings